Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
85 hedge funds and large institutions have $997M invested in Karuna Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 8 closing their positions.
576% more capital invested
Capital invested by funds: $147M → $997M (+$849M)
513% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 8
70% more funds holding
Funds holding: 50 → 85 (+35)
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$83.4M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$26.3M |
| 3 |
BlackRock
New York
|
+$15.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$11.4M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$7.9M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$6.57M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.55M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.23M |
KRTX Hedge Fund Activity: Q4 2019 in Review
85 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2019, worth a combined $997M — up 576% from $147M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new KRTX positions and 8 closed out — a net gain of 41 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $83.4M. The largest seller was Fidelity International, cutting an estimated $11.4M.
- 85 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2019, up from 50 in Q3 2019.
- Funds reported $997M of Karuna Therapeutics, Inc. Common Stock stock for Q4 2019, up 576% quarter-over-quarter.
- 49 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of +41 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2019 was Fidelity Investments, an estimated $83.4M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2019 was Fidelity International, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2019.